Career history of Keith Vendola
Former positions of Keith Vendola
Companies | Position | Start | End |
---|---|---|---|
IO BIOTECH, INC. | Director of Finance/CFO | 01/07/2021 | 09/05/2022 |
REZOLUTE, INC. | Director of Finance/CFO | 16/05/2018 | 06/11/2020 |
Corporate Officer/Principal | 06/11/2020 | 01/03/2021 | |
COHERUS BIOSCIENCES, INC. | Human Resources Officer | 01/05/2015 | 01/06/2017 |
Eiger BioPharmaceuticals, Inc. /Old/
Eiger BioPharmaceuticals, Inc. /Old/ Pharmaceuticals: MajorHealth Technology Eiger BioPharmaceuticals, Inc. provides pharmaceutical products. It operates as a biopharmaceutical company, which focuses on the discovery and development of new antiviral agents against novel targets in the treatment of hepatitis. The firm’s pipeline includes clinical stage assets and preclinical new chemical entities (NCEs) shown to possess antiviral activity against Hepatitis C, Hepatitis D, and a wide array of other viruses. It also conducts multiple clinical proofs of concept studies in multiple clinical sites in HCV and HDV patients. The company was founded by Jeffrey S. Glenn in 2008 and is headquartered in Palo Alto, CA. | Director of Finance/CFO | 01/03/2010 | - |
Threshold Pharmaceuticals, Inc.
Threshold Pharmaceuticals, Inc. BiotechnologyHealth Technology Threshold Pharmaceuticals, Inc. engages in the development of therapeutics for treating tumors. It offers the Evofosfamide which designed as a prodrug that is activated under the extreme hypoxic conditions commonly found in tumors, but not typically in healthy tissues, and TH-3424 which is a small-molecule drug candidate for the treatment of liver, castrate resistant prostate cancer, T-cell acute lymphoblastic leukemias, and other cancers. The company was founded by Jeffrey W. Bird on October 17, 2001 and is headquartered in South San Francisco, CA | Corporate Officer/Principal | - | - |
DiObex, Inc.
DiObex, Inc. Pharmaceuticals: MajorHealth Technology DiObex, Inc. develops therapies for metabolic disease treatment. Its products address the markets for the treatment of diabetes and its co-morbidities such as hypertension, dyslipidemia, and visceral adiposity. The company was founded in 2003 and is headquartered in San Francisco, CA. | Corporate Officer/Principal | 01/10/2007 | - |
Training of Keith Vendola
College of the Holy Cross (Massachusetts) | Undergraduate Degree |
Dartmouth Medical School | Doctorate Degree |
Kellogg School of Management | Masters Business Admin |
Statistics
International
United States | 9 |
Denmark | 2 |
Operational
Corporate Officer/Principal | 3 |
Director of Finance/CFO | 3 |
Undergraduate Degree | 1 |
Sectoral
Health Technology | 7 |
Consumer Services | 4 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
Listed companies | 3 |
---|---|
REZOLUTE, INC. | Health Technology |
COHERUS BIOSCIENCES, INC. | Health Technology |
IO BIOTECH, INC. | Health Technology |
Private companies | 3 |
---|---|
DiObex, Inc.
DiObex, Inc. Pharmaceuticals: MajorHealth Technology DiObex, Inc. develops therapies for metabolic disease treatment. Its products address the markets for the treatment of diabetes and its co-morbidities such as hypertension, dyslipidemia, and visceral adiposity. The company was founded in 2003 and is headquartered in San Francisco, CA. | Health Technology |
Threshold Pharmaceuticals, Inc.
Threshold Pharmaceuticals, Inc. BiotechnologyHealth Technology Threshold Pharmaceuticals, Inc. engages in the development of therapeutics for treating tumors. It offers the Evofosfamide which designed as a prodrug that is activated under the extreme hypoxic conditions commonly found in tumors, but not typically in healthy tissues, and TH-3424 which is a small-molecule drug candidate for the treatment of liver, castrate resistant prostate cancer, T-cell acute lymphoblastic leukemias, and other cancers. The company was founded by Jeffrey W. Bird on October 17, 2001 and is headquartered in South San Francisco, CA | Health Technology |
Eiger BioPharmaceuticals, Inc. /Old/
Eiger BioPharmaceuticals, Inc. /Old/ Pharmaceuticals: MajorHealth Technology Eiger BioPharmaceuticals, Inc. provides pharmaceutical products. It operates as a biopharmaceutical company, which focuses on the discovery and development of new antiviral agents against novel targets in the treatment of hepatitis. The firm’s pipeline includes clinical stage assets and preclinical new chemical entities (NCEs) shown to possess antiviral activity against Hepatitis C, Hepatitis D, and a wide array of other viruses. It also conducts multiple clinical proofs of concept studies in multiple clinical sites in HCV and HDV patients. The company was founded by Jeffrey S. Glenn in 2008 and is headquartered in Palo Alto, CA. | Health Technology |
- Stock Market
- Insiders
- Keith Vendola
- Experience